ReviewCurrent problems in cardiology2016
Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects.
Review in Current problems in cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 121 citations in OpenAlex.
- Phase 2 Re-Entry Without IJACC. Clinical electrophysiology · 2023Trial
- Discovery of a novel NaActa pharmacologica Sinica · 2026Article
- Interpretable Deep Learning Models for Arrhythmia Classification Based on ECG Signals Using PTB-X Dataset.Diagnostics (Basel, Switzerland) · 2025Article
- Genetic Basis of Brugada Syndrome.Biomedicines · 2025Review
- Fever as a Catalyst for Life-Threatening Arrhythmias in Brugada Syndrome: A Rare Case of Brugada Syndrome Unmasked in a Young Male.Clinical case reports · 2025Article
- Artificial intelligence for Brugada syndrome diagnosis and gene variants interpretation.American journal of cardiovascular disease · 2025Review
- Identification of Lauric Acid as a Potent Sodium Channel NaDrug design, development and therapy · 2025Article
- Fever, Syncope, and the Brugada Dilemma: Navigating the Complexities of ICD Decision-Making in an Atypical Presentation.Case reports in cardiology · 2025Article
- NaV1.5 autoantibodies in Brugada syndrome: pathogenetic implications.European heart journal · 2024Article
- Deceptive Anteroseptal ST-segment Elevation and Brugada Pattern Caused by Isolated Conus Artery Occlusion.Arquivos brasileiros de cardiologia · 2024Article
- Whole-heart computational modelling provides further mechanistic insights into ST-elevation in Brugada syndrome.International journal of cardiology. Heart & vasculature · 2024Article
- Brugada syndrome update.Frontiers in physiology · 2024Review
- Electrocardiographic temporo-spatial assessment of depolarization and repolarization changes after epicardial arrhythmogenic substrate ablation in Brugada syndrome.European heart journal. Digital health · 2023Article
- Review
- Brugada Syndrome: More than a Monogenic Channelopathy.Biomedicines · 2023Review
- Review
- Anesthesia in patients with Brugada syndrome: two case reports.Journal of medical case reports · 2023Article
- Hepatogastric fistula: a complication of pyogenic liver abscess in a patient with the Brugarda syndrome - A rare case report.Annals of medicine and surgery (2012) · 2023Article
- Brugada Syndrome: From Molecular Mechanisms and Genetics to Risk Stratification.International journal of molecular sciences · 2023Review
- Case report: State-of-the-art risk-modifying treatment of sudden cardiac death in an asymptomatic patient with a mutation in the SCN5A gene and a review of the literature.Frontiers in cardiovascular medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Brugada syndrome (BrS) is an inherited cardiac arrhythmia syndrome first described as a new clinical entity in 1992. Electrocardiographically characterized by distinct coved type ST segment elevation in the right-precordial leads, the syndrome is associated with a high risk for sudden cardiac death in young adults, and less frequently in infants and children. The electrocardiographic manifestations of BrS are often concealed and may be unmasked or aggravated by sodium channel blockers, a febrile state, vagotonic agents, as well as by tricyclic and tetracyclic antidepressants. An implantable cardioverter defibrillator is the most widely accepted approach to therapy. Pharmacologic therapy is designed to produce an inward shift in the balance of currents active during the early phases of the right ventricular action potential (AP) and can be used to abort electrical storms or as an adjunct or alternative to device therapy when use of an implantable cardioverter defibrillator is not possible. Isoproterenol, cilostazol, and milrinone boost calcium channel current and drugs like quinidine, bepridil, and the Chinese herb extract Wenxin Keli inhibit the transient outward current, acting to diminish the AP notch and thus to suppress the substrate and trigger for ventricular tachycardia or fibrillation. Radiofrequency ablation of the right ventricular outflow tract epicardium of patients with BrS has recently been shown to reduce arrhythmia vulnerability and the electrocardiographic manifestation of the disease, presumably by destroying the cells with more prominent AP notch. This review provides an overview of the clinical, genetic, molecular, and cellular aspects of BrS as well as the approach to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.